

## Lung function and breathing patterns in hospitalised COVID-19 survivors

Stockley, James A; Alhuthail, Eyas A; Coney, Andrew M; Parekh, Dhruv; Geberhiwot, Tarekegn; Gautum, Nandan; Madathil, Shyam C; Cooper, Brendan G

DOI:

[10.1186/s12931-021-01834-5](https://doi.org/10.1186/s12931-021-01834-5)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Stockley, JA, Alhuthail, EA, Coney, AM, Parekh, D, Geberhiwot, T, Gautum, N, Madathil, SC & Cooper, BG 2021, 'Lung function and breathing patterns in hospitalised COVID-19 survivors: a review of post-COVID-19 Clinics', *Respiratory research*, vol. 22, no. 1, 255. <https://doi.org/10.1186/s12931-021-01834-5>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

RESEARCH

Open Access



# Lung function and breathing patterns in hospitalised COVID-19 survivors: a review of post-COVID-19 Clinics

James A. Stockley<sup>1\*</sup> , Eyas A. Alhuthail<sup>2,3</sup>, Andrew M. Coney<sup>2</sup>, Dhruv Parekh<sup>4,5</sup>, Tarekegn Geberhiwot<sup>6</sup>, Nandan Gautum<sup>4</sup>, Shyam C. Madathil<sup>7</sup> and Brendan G. Cooper<sup>1,2</sup> 

## Abstract

**Introduction:** There is relatively little published on the effects of COVID-19 on respiratory physiology, particularly breathing patterns. We sought to determine if there were lasting detrimental effect following hospital discharge and if these related to the severity of COVID-19.

**Methods:** We reviewed lung function and breathing patterns in COVID-19 survivors > 3 months after discharge, comparing patients who had been admitted to the intensive therapy unit (ITU) (n = 47) to those who just received ward treatments (n = 45). Lung function included spirometry and gas transfer and breathing patterns were measured with structured light plethysmography. Continuous data were compared with an independent t-test or Mann Whitney-U test (depending on distribution) and nominal data were compared using a Fisher's exact test (for 2 categories in 2 groups) or a chi-squared test (for > 2 categories in 2 groups). A p-value of < 0.05 was taken to be statistically significant.

**Results:** We found evidence of pulmonary restriction (reduced vital capacity and/or alveolar volume) in 65.4% of all patients. 36.1% of all patients has a reduced transfer factor ( $TL_{CO}$ ) but the majority of these (78.1%) had a preserved/increased transfer coefficient ( $K_{CO}$ ), suggesting an extrapulmonary cause. There were no major differences between ITU and ward lung function, although  $K_{CO}$  alone was higher in the ITU patients ( $p = 0.03$ ). This could be explained partly by obesity, respiratory muscle fatigue, localised microvascular changes, or haemosiderosis from lung damage. Abnormal breathing patterns were observed in 18.8% of subjects, although no consistent pattern of breathing pattern abnormalities was evident.

**Conclusions:** An "extrapulmonary restrictive" like pattern appears to be a common phenomenon in previously admitted COVID-19 survivors. Whilst the cause of this is not clear, the effects seem to be similar on patients whether or not they received mechanical ventilation or had ward based respiratory support/supplemental oxygen.

**Keywords:** Interstitial Lung Disease, Respiratory Physiology, Ventilation, Infectious Disease, Critical Care and Emergency Medicine

## Introduction

The severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), which emerged from Wuhan, China in December 2019 has developed into the COVID-19 global pandemic [1]. It has become one of the most studied infections in recent medical history with a plethora of publications on pathology, immunology, physiology and

\*Correspondence: james.stockley@uhb.nhs.uk

<sup>1</sup> Lung Function and Sleep, Outpatient Department Area 3, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2GW, UK  
Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

virology in multiple areas of clinical specialisation. There is relatively little information published on lung function in survivors of moderate to severe disease. Furthermore, we had observed acutely that many COVID-19 survivors seem to display acute dysfunctional breathing patterns during and after their infection.

COVID-19, whilst being a multi-organ infection, is characterised primarily as a respiratory infection that often leads to pneumonia and significant pulmonary vascular complications. Like other pneumonias (SARS, MERS), early reports show that COVID-19 produces a sustained restrictive lung function pattern after survivors are discharged from hospital (at least 3 months post-hospital discharge) when reviewed in COVID-19 follow up clinics [2–5]. However, to date no published papers have reported looking for the assessment of dysfunctional breathing in COVID-19 survivors. Nevertheless, much work is now focussing on the treatment of post-COVID-19 symptoms including tackling dyspnoea, fatigue, and dysfunctional breathing [6].

We sought to determine if pulmonary restriction was evident in patients admitted with COVID-19 to the University Hospitals Birmingham NHS Foundation Trust and, importantly, whether the pattern of restriction was still evident 3 months after discharge and whether it was more consistent with interstitial damage or an extrapulmonary cause. In addition, we wanted to explore the possibility of dysfunctional breathing in these patients (using a novel technique).

We also hypothesised that hospitalised patients who had COVID-19 and attended ITU would have worse lung function than those who had been admitted with COVID-19 to the ward only. Therefore, we compared all physiological outcomes between these two cohorts.

We reviewed lung function in sequential Post-COVID-19 Review Clinic patients who had been hospitalised and qualified for our post-COVID-19 Review Clinic. These included patients who had been admitted to hospital, to a secondary care ward with or without an ITU admission and required a  $\text{FiO}_2 > 40\%$ .

We compared routine lung function (spirometry and gas transfer mainly) and breathing pattern assessment assessed by structured light plethysmography (SLP) in those who were admitted to wards only with those who spent time mechanically ventilated on ITU.

## Methods

Routine lung function testing was performed at our lung function department using MedGraphics Ultima equipment (MGC UK, Gloucester, UK) to recognised testing standards and quality control [7–11] and included spirometry and gas transfer in most patients, with a few also having lung volume estimation by

nitrogen washout. As this was data from routine clinics, not all patients did every test (see “Results”) because they had other extensive assessments at these clinic appointments. Spirometry parameters included  $\text{FEV}_1$ , FVC,  $\text{FEV}_1/\text{FVC}$ , VC and PEF, whilst single breath carbon monoxide gas transfer test measured gas transfer ( $\text{TL}_{\text{CO}}$ ), transfer coefficient ( $\text{K}_{\text{CO}}$ ) (both corrected for haemoglobin concentration) and alveolar volume ( $\text{V}_A$ ).  $\text{V}_A$  in the absence of any airflow obstruction was used as a surrogate for total lung capacity (TLC). However, a few patients in each group were able to perform measurements of TLC when time allowed in this busy clinic.

Reference ranges included Global Lung Initiative (GLI) [12] for spirometry and European Coal and Steel Community (ECSC) [13] for gas transfer and lung volumes. All data (Table 2) were presented as absolute values, percent of predicted (%predicted) and as standardised residuals (SR), with SR values  $< -1.64$  SR deemed to be below the normal range and values  $> 1.64$  SR above the normal range [8].

Patients also had their breathing patterns assessed using the Thora 3Di Structured Light Plethysmography (SLP) device (*Pneumacare, Ely, UK*), which is an opto-plethysmographic, non-invasive measurement of chest wall and abdominal motion [14, 15]. Parameters of interest derived from SLP include relative thoracic contribution (RTC), duty cycle (ratio of inspiratory time to total breath time;  $\text{Ti}:\text{T}_{\text{tot}}$ ), abdominal-thoracic phase angle (PA), respiratory rate (RR), and the inspiratory:expiratory flow ratio at 50% tidal volume (IE50). The variation (entropy) of breathing was also calculated from the standard deviation of breath to breath (SDBB) interval and the root mean square of the successive differences between each breath (RMSSD). Values were compared with novel reference ranges [16].

Patients who tested positive for COVID-19 and had moderate to severe symptoms required supplemental oxygen of  $> 40\%$  were included in the clinics [17]. All patients who remained on wards were not ventilated (neither NIV nor nasal CPAP), but all patients admitted to ITU received mechanical ventilation requiring intubation and sedation. The only exclusion to the review was the inability to perform acceptable lung function tests.

All statistical analyses were performed using IBM® SPSS® Statistics Version 24 (Portsmouth, UK). Data distribution was initially assessed by a Shapiro–Wilk test and confirmed by visual analysis of the stem-leaf plots. Continuous data were compared between groups using either an independent t-test or a Mann Whitney-U test, depending on the distribution. Nominal data were compared between groups using either a Fisher’s exact test (for 2 categories in 2 groups) or a chi-squared test (for  $> 2$

categories in 2 groups). A p-value of  $<0.05$  was taken to be statistically significant for all analyses.

## Results

### Subjects

64 male and 28 female COVID-19 survivors had their lung function measured. 45 had been treated on wards and 47 were admitted to ITU. More males with COVID required hospitalisation, with 38 (80.9%) males being admitted to ITU compared with 26 (57.8%) treated on wards ( $p=0.04$ ). Only 3 patients were current smokers, 28 ex-smokers with the rest having never smoked significantly. There were no differences in smoking status between the ITU and ward patients. Body habitus showed 65.2% obese, 28.3% overweight, 5.4% within the normal range and 1.1% underweight. There were no statistical differences in BMI between the two groups. Whilst there were more Asian patients on ITU and fewer black patients, overall the ethnicities were not statistically different. There were similar numbers of Caucasian patients in both groups. The mean (SD) duration of admission for ITU and ward patients was 40.3 (16.6) versus 9.2 (5.8) days, respectively. Underlying chronic conditions such as diabetes, respiratory and cardiac disorders have not been identified. Table 1 summarises the anthropometric data (age, sex, weight and BMI), ethnicity and clinical data.

All lung function data are summarised in Table 2. There were no differences in spirometry between the ward and ITU patients (Fig. 1). Interestingly, only 2 patients showed evidence of peripheral airflow obstruction ( $FEV_1/FVC < -1.64$  SR) and none showed evidence of upper airway obstruction (defined as an Empey index  $>10$ ).

We observed evidence of pulmonary restriction ( $FVC$  and/or  $V_A < -1.64$  SR) in 52 patients (55.3%), which has been previously reported in other COVID-19 studies [2–5]. In a small subgroup that performed lung volumes, reduction in TLC was confirmed but lung volumes results not different between ward and ITU patients.

We confirmed the reduction in gas transfer ( $TL_{CO}$ ) in 32 patients (34.0%) but also noted the relative preservation/increase in  $K_{CO}$  in the majority (78.1%) of these. Although  $TL_{CO}$  was not different between the two groups,  $K_{CO}$  SR was significantly higher on average in ITU patients ( $p=0.03$ ) (Fig. 2). Although there was a large degree of data overlap, there was a tendency for ward patients to show a more “parenchymal” pattern (decreases in both  $TL_{CO}$  and  $K_{CO}$  together) whereas ITU survivors showed a more “extrapulmonary” pattern (reduced  $TL_{CO}$  with a normal or raised  $K_{CO}$ ) (Fig. 3). Oxygen saturation on air at rest was normal (94–98%) in all patients.

**Table 1** Anthropometric and clinical data for COVID-19 survivors

	Ward	ITU	All
N=	45	47	92
Male: Female	26 M: 19F	38 M: 9F*	64 M: 28F
Age (years)	54.7 (24.0–83.0)	55.5 (21.0–77.0)	56.0 (21.0–83.0)
Weight (kg)	87.0 (78.0–105.0)	93.0 (86.5–107.9)	91.5 (79.8–106.2)
BMI (kg/m <sup>2</sup> )	30.7 (28.2–35.6)	32.2 (29.8–37.1)	31.8 (28.7–35.89)
Underweight	1 (2.1%)	0 (0.0%)	1 (1.1%)
Normal	3 (6.7%)	6 (12.8%)	10 (10.8%)
Overweight	16 (35.6%)	10 (21.3%)	27 (29.3%)
Obese	25 (55.5%)	31 (66.0%)	54 (58.7%)
Ethnicity			
Asian	14 (31.1%)	21 (44.7%)	35 (38.0%)
Black	5 (11.1%)	1 (2.1%)	6 (6.5%)
Caucasian	24 (53.3%)	24 (51.1%)	48 (52.2%)
SE Asian	2 (4.4%)	1 (2.1%)	3 (3.3%)
Smoking history			
Current	2 (4.4%)	1 (2.1%)	3 (3.3%)
Ex	14 (31.1%)	13 (27.7%)	28 (30.4%)
Never	29 (64.4%)	31 (70.2%)	52 (64.1%)
Haemoglobin (g/L)	129.6 (2.7)	136.0 (2.2)	133.0 (1.8)
< 120 g/L	7 (14.9%)	12 (25.5%)	19 (20.2%)
Admission Details (days)			
Ward Duration	9.2 (5.8)	13.6 (8.8)	–
ITU Duration	n/a	26.3 (9.2)	–
In-Patient Stay	9.2 (5.8)	40.3 (16.6)	–

Patients include those treated on medical wards only (Ward), those that attended intensive therapy unit (ITU) and the total group (ALL). Age is presented as Mean (range), Admission Details are presented as Mean (SD), and all other data are presented as Mean (SE), Median (IQR), or number (% cohort). The only significant difference was the proportion of males to females, where there was a higher proportion of males on ITU versus Ward (\* $p=0.02$ )

Some COVID-19 survivors who performed SLP showed abnormality in duty cycle, phase angle and respiratory rate (21.8%, 22.1% and 19.5% abnormality, respectively) compared with reference values. However, there were no statistical differences in SLP measurements between the patients from ITU and those from the ward, including assessments of entropy (Fig. 4).

## Discussion

Our data concur with other lung function reports of COVID-19 survivors [2–5] by showing a restrictive pattern with a reduction in overall gas transfer ( $TL_{CO}$ ) in a proportion of COVID-19 survivors. Pulmonary fibrosis is a recognised sequela of both Adult Respiratory Distress Syndrome (ARDS) and barotrauma due to high pressure mechanical ventilation and may be a contributing factor on COVID-19 patients treated on ITU and, possibly, those treated with high CPAP pressures on the ward (although very few patients received CPAP at University

**Table 2** Lung function data summary for COVID-19 survivors


	WARD				ITU				ALL			
	Absolute		% Abnormal		Absolute		% Abnormal		Absolute		% Abnormal	
	N=45	% Predicted	SR	N=45	N=42	% Predicted	SR	N=87	% Predicted	SR	N=87	% Abnormal
<b>Spirometry</b>												
FEV <sub>1</sub>	2.76 (0.11)	88.6 (2.6)	-0.73 (0.18)	23	2.81 (0.12)	85.5 (2.7)	-1.02 (0.20)	26	2.78 (0.08)	87.1 (1.86)	-0.87 (0.13)	23
FVC	3.32 (0.14)	84.6 (2.4)	-1.09 (0.19)	21	3.40 (0.16)	81.3 (2.7)	-1.39 (0.21)	34	3.36 (0.10)	83.0 (1.81)	-1.24 (0.14)	26
FEV <sub>1</sub> /FVC %	84.7 (79.5-88.3)	106.0 (100.0-109.5)	0.74 (0.12-1.41)	2	84.8 (81.8-87.6)	107.0 (103.0-109.8)	0.94 (0.43-1.31)	1	84.7 (80.8-88.2)	107.0 (101.0-110.0)	0.86 (0.23-1.35)	2
PEF	8.48 (6.91-10.25)	113.0 (100.5-123.5)	0.90 (0.07-1.69)	6	8.99 (7.32-9.81)	110.0 (100.3-123.8)	0.71 (0.04-1.70)	4	8.67 (7.02-10.24)	112.0 (100.0-124.0)	0.85 (0.01-1.74)	5
VC	3.44 (0.13)	87.4 (2.1)	-0.78 (0.16)	13	3.45 (0.15)	82.5 (2.6)	-1.14 (0.19)	30	3.44 (0.10)	84.8 (1.7)	-0.97 (0.13)	20
Empey Index	5.67 (4.77-6.26)	-	-	0	5.42 (4.74-6.08)	-	-	0	5.49 (4.74-6.21)	-	-	0
<b>Lung volumes</b>												
TLC	4.78 (4.45-5.41)	80.0 (73.8-82.5)	-1.70 (-2.21-1.67)	75	5.15 (4.77-5.59)	79.5 (75.8-81.5)	-1.87 (-2.14-1.70)	75	5.07 (4.71-5.41)	80.0 (75.0-82.3)	-1.79 (-2.17-1.67)	75
FRC	2.43 (1.99-2.82)	70.0 (65.0-79.8)	-1.52 (-2.00-1.17)	38	2.42 (2.19-2.75)	72.0 (63.5-82.8)	-1.50 (-2.11-1.01)	38	2.42 (2.06-2.82)	70.5 (63.5-82.0)	-1.50 (-2.11-1.08)	38
RV	1.50 (1.32-1.81)	70.0 (61.8-76.8)	-1.51 (-1.79-1.16)	50	1.73 (1.70-1.84)	81.5 (76.0-84.5)	-0.91 (-1.10-0.80)	13	1.72 (1.44-1.84)	75.0 (69.3-84.5)	-1.16 (-1.68-0.80)	25
<b>Gas transfer</b>												
TLco	7.17 (0.25)	79.1 (1.9)	-1.40 (0.13)	40	7.58 (0.33)	81.1 (2.07)	-1.23 (0.14)	38	7.36 (0.21)	80.1 (1.4)	-1.31 (0.10)	36
Kco	1.53 (1.36-1.66)	97.0 (86.5-108.0)	-0.26 (-1.00-0.52)*	10	1.55 (1.43-1.73)	105.0 (95.8-114.0)	0.27 (-0.32-0.82)*	8	1.54 (1.42-1.71)	102.0 (90.0-112.8)	-0.05 (-0.75-0.73)	8
VA	4.62 (0.14)	80.2 (2.0)	-1.76 (0.19)	51	4.91 (0.18)	77.6 (1.9)	-2.02 (0.18)	53	4.75 (0.12)	79.0 (1.4)	-1.87 (0.13)	50
<b>SLP</b>												
RTc	46.71 (2.06)	84.64 (3.63)	-0.64 (0.15)	11	49.88 (2.05)	92.39 (3.81)	-0.35 (0.17)	9	48.08 (1.47)	87.98 (2.66)	-0.51 (0.11)	10
IE50	1.31 (0.06)	100.4 (4.4)	0.11 (0.16)	14	1.32 (0.04)	107.1 (3.5)	0.32 (0.23)	18	1.34 (0.04)	103.8 (2.9)	0.24 (0.13)	15
Ti:Tot	0.40 (0.01)	104.7 (3.7)	0.58 (0.36)	23	0.43 (0.01)	106.1 (1.6)	0.71 (0.19)	21	0.41 (0.01)	101.9 (2.3)	0.37 (0.22)	22
PA	4.70 (3.60-8.50)	132.0 (93.6-236.9)	0.50 (-0.09-1.64)	28	5.50 (3.70-6.75)	154.3 (97.2-191.4)	0.81 (-0.18-1.25)	14	5.10 (3.60-7.60)	138.8 (93.8-214.5)	0.73 (-0.12-1.52)	22
RR	15.95 (0.93)	111.4 (6.3)	0.53 (0.22)	21	17.71 (0.88)	119.1 (6.0)	0.57 (0.21)	21	16.70 (0.65)	112.0 (4.5)	0.39 (0.16)	19
SDBB	0.41 (0.16-0.75)	-	-	-	0.31 (0.17-0.54)	-	-	-	0.36 (0.16-0.64)	-	-	-

**Table 2** (continued)

	<b>N = 45</b>	<b>N = 34</b>	<b>N = 79</b>
<b>SLP</b>			
RMSSD	0.38 (0.17–0.86)	0.34 (0.18–0.61)	0.37 (0.18–0.72)
<b>Oximetry</b>	<b>N = 45</b>	<b>N = 47</b>	<b>N = 92</b>
SpO <sub>2</sub>	97 (96–98)	97 (96–97)	97 (96–98)

Of all lung function parameters, only K<sub>CO</sub> was statistically different, with a higher SR value being observed in ITU patients compared to those treated on the ward (\*p = 0.03). Patients include those treated on medical wards only (WARD), those who attended intensive therapy unit (ITU) and the total group (ALL). Absolute, % predicted and SR values are displayed as either Mean (SE) or Median (IQR), depending on the distribution of data. Normality is defined as an SR value between -1.64 and 1.64

**Spirometry:** Forced Expiratory Volume in 1 s (FEV<sub>1</sub>), Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF), Relaxed Vital Capacity (VC), Lung volumes: Total Lung Capacity (TLC), Residual Volume (RV) and Functional Residual Capacity (FRC); Gas transfer: Transfer Factor (TL<sub>CO</sub>), Transfer Coefficient (K<sub>CO</sub>) and Alveolar Volume (V<sub>A</sub>) for single breath carbon monoxide test. All volumes are expressed in litres corrected for body temperature and pressure saturated with water (BTPS). TL<sub>CO</sub> is expressed in (mmol/kPa/min) and K<sub>CO</sub> in (mmol/kPa/min/L). Empey Index is FEV<sub>1</sub>/PEF in (mL/L/min). SLP values include: Relative Thoracic Contribution (RTC) expressed as a percentage (%), Inspiratory:Expiratory flow at 50% of tidal volume (IE50), Duty Cycle (Ti:Tot) is the ratio of time of inspiration to total breathing cycle time, Phase Angle (PA) is expressed in degrees and Respiratory Rate (RR) is expressed in breaths per minute. The variability of breathing is expressed as the Standard Deviation of the Breath by Breath interval (SDBB) and the Root Mean Square Standard Deviation (RMSSD)




Hospitals Birmingham during the first COVID-19 wave). However, we also note the relatively preserved or slightly raised  $K_{CO}$  in 78.1% of these patients, which is usually more consistent with an extrapulmonary pathology. Our data suggest that this pattern of physiological dysfunction may be even more pronounced in COVID-19 patients admitted to ITU who were treated on the ward alone (and weren't intubated or mechanically ventilated). This pattern was also reported by Mo et al. [2] but was not sufficiently explained. We have considered several possible explanations for this pattern including, Intussusceptive angiogenesis (remnants of lung vascular changes from COVID-19), pulmonary haemosiderosis, and extrapulmonary restriction (obesity, pleural issues or muscle weakness).

The most common cause of this pattern is extrapulmonary restriction, with obesity being the most likely cause [18]. Indeed given the body habitus of all our patients to be predominantly overweight/obese, this seems a likely hypothesis. However, reviewing the literature suggests that this pattern is usually only observed in severe obesity (BMI > 40) [19]. Only 4 ward and 9 ITU patients were above this threshold, so excessive obesity is unlikely to be the sole reason for this pattern. Although extrapulmonary restriction is more associated with upper body fat [20], we didn't collect this data in our patients.

Several studies suggest that the reduction in volume caused by obesity was insufficient to explain the increase of  $K_{CO}$  found in patients with small lung volumes [18, 21]. Usually,  $TL_{CO}$  in healthy subjects decreases as the inspired volume reduces at a rate of about 3.3% per 10% decrease of vital capacity. In this current study, the inspired volume ( $V_i$ ) was 94.8% (3.6%) of the vital capacity (VC) indicating a close match of  $V_i$  with VC. On average, VC was reduced by about 15% which would mean  $V_i$  should have been reduced by about 5%, but it was reduced by around 15% which suggests more than an obesity effect. It is understood that there is a relative increase in capillary blood volume in obesity that is thought to lead to the increase in gas transfer [22].

Whilst the COVID-19 survivors in the Mo et al. [2] study also showed the same reduced  $TL_{CO}$  with raised  $K_{CO}$  pattern, their population all had a mean BMI below 25, which suggests that the phenomenon is not related to obesity causing extrapulmonary restriction.

Muscle weakness causing extrapulmonary restriction would show a reduction in muscle pressures. Intensive Care Unit Acquired Weakness (ICUAW) is a well-recognised phenomenon that could potentially cause weakness of the respiratory pump. Logically, this would be more prevalent in COVID-19 survivors treated on ITU but may also be a contributing factor for patients treated on wards



**Fig. 2** Box and whisker plots comparing  $TL_{CO}$  and  $K_{CO}$  in COVID-19 survivors.  $TL_{CO}$  and  $K_{CO}$  are displayed together to demonstrate how  $TL_{CO}$  is reduced on average, whereas  $K_{CO}$  is generally preserved (ward) or raised (ITU). Indeed,  $K_{CO}$  was significantly higher in ITU patients compared to those treated on the ward ( $p = 0.03$ ). Patients include those who were treated on ITU (light grey boxes) and those who were treated on the ward alone (dark grey boxes). Boxes represent the IQR with the median line displayed. Whiskers represent  $1.5 \times$  IQR to highlight outliers


who remained virtually bed-bound for long durations. Although we didn't measure respiratory muscle function, Huang et al. recently showed normal maximal inspiratory/expiratory muscle pressures in post-COVID-19 survivors [3], which argues against this hypothesis. There is no suspicion from the recent COVID-19 literature that respiratory muscle weakness is a feature of COVID-19 recovery, although neuropathy and general fatigue have been noted as a key symptom in sick and recovering patients.

A high  $K_{CO}$  indicates a predominance of pulmonary capillary volume ( $V_c'$ ) over alveolar volume, which may arise for different reasons. Incomplete alveolar expansion but preserved gas exchange units frequently lead to a  $K_{CO}$  of 120–140% predicted or even higher (i.e. extra-parenchymal restriction, such as pleural, chest wall or neuromuscular disease) [21–24]. Pleural and interstitial changes have been identified in COVID-19 patients using imaging [25–29] and at autopsy [30]. Alternatively, an increase in pulmonary blood flow from areas of diffuse

(pneumonectomy) or localised (local destructive lesions/atelectasis) loss of gas exchange units to areas with preserved parenchyma can lead to more modest increases in  $K_{CO}$ . However, a high  $K_{CO}$  can also be seen with normal or near-normal  $V_A$  when there is increased pulmonary blood flow or redistribution (e.g. a left-to-right shunt or asthma). Intussusceptive angiogenesis [31] as a result of chronic infection is a dynamic intravascular process that can modify the structure of the microcirculation. Recently, this has been shown to be present at autopsy in COVID-19 patients [32] and could explain some or most of the rise in  $K_{CO}$  observed.

Haemosiderosis, which is the deposition of extravascular haemoglobin, may also be a cause. Alveolar haemorrhage is a possible mechanism given the vascular destruction reported in active COVID-19 and fits with the lung function results. In haemosiderosis, macrophages convert the iron in haemoglobin into haemosiderin within 36–72 h [33, 34] and the haemosiderin-laden macrophages can reside for up to 4–8 weeks in the






lungs. Pulmonary haemosiderosis is usually considered to be from persistent or recurrent intra-alveolar bleeding, which may explain the symptoms of “long COVID” and the time course of improvement in symptoms. The effect of haemosiderosis on interpretation of the gas transfer test has been highlighted by Hughes [18, 35]. However, there was only mild anaemia (haemoglobin  $<120$  g/L) in 7 (14.9%) of the ward patients and 12 (25.5%) of ITU patients and all gas transfer tests were corrected for haemoglobin. This makes haemosiderosis an unlikely explanation for most of the abnormalities we observed in gas transfer.

Another explanation for the reduced  $TL_{CO}$ /raised  $K_{CO}$  pattern could be the development of necrotising pulmonary capillaritis occurring in isolation [36]. This arises from diffuse interstitial neutrophilic infiltration with cell fragmentation and, because of apoptosis, cellular accumulation within the lung tissue, filling

the interstitial space. This can lead to expansion and fibrinoid necrosis. As a result of these processes, the integrity of interstitial capillaries is damaged, allowing red blood cells to pass through the alveolar capillary basement membranes, freely enter the interstitial compartment and flood alveolar spaces. Clinically, this diffuse alveolar microhaemorrhage enables the CO in the gas transfer test to combine with this “occult” blood or haem from haemosiderosis and effectively raise the  $K_{CO}$ . However, global gas transfer ( $TL_{CO}$ ) is not as affected because of the counteractive restrictive defect that causes a decrease in lung volume and, hence, alveolar surface area which, in turn, has a greater effect on decreasing the  $TL_{CO}$  than the rise due to the diffuse local haemorrhage.

A similar  $TL_{CO}$  and  $K_{CO}$  pattern seen in SARS [37] was thought to be the result of muscle wasting and corticosteroid induced myopathy. We have insufficient data



to prove or disprove this hypothesis currently so, even though it is unlikely, it cannot be excluded.

More males than females (as reported elsewhere in COVID-19) required assisted ventilation/oxygenation on ITU and, therefore, probably had worse infections. These hospitalised patients were predominantly overweight/obese, which is another known risk factor in severe COVID-19 for an increased likelihood of hospitalisation, ITU admission and morbidity. Ethnicity is also known to be a factor associated with an increase in incidence and severity of COVID-19 in patients from black, Asian and minority ethnic (BAME) communities in the UK [38]. However, we did not note any significant differences in ethnicity between ITU and ward patients, so this does not appear to be causal in the outcome of the gas transfer tests.

There were no major differences in lung function between ward and ITU patients that could clearly differentiate ward and ITU patients, despite a statistically lower  $K_{CO}$  on average in ITU patients (where there was much overlap between the two cohorts). It might have been expected that patients who had had mechanical ventilation for severe COVID pneumonitis to have had a more obvious and distinct pattern of lung function impairment but this wasn't the case at 3+ months.

Our data also show that few of the patients had any evidence of airflow obstruction on spirometry ( $FEV_1/FVC$  SR) and that never-smokers showed greater hospitalisation but this may be because smokers (more likely to have COPD) either shielded from COVID-19 and never got the infection, or died on ITU and weren't followed up. Some may interpret this as evidence of the "protective effect" of smoking in COVID-19 [39].

#### Breathing patterns

The anticipated alteration in breathing patterns was not evident when compared with reference values. The ITU patients had no more dysfunctional breathing patterns than the ward patients. Whilst many post-ITU patients display dysfunctional breathing immediately on leaving ITU, it appears to improve rapidly in most, so by 3+ months there are only 20% showing abnormality.

These abnormal SLP values were both lower and greater than the normal range with no consistent pattern. We had wondered whether SLP could have been used to detect dysfunctional breathing patterns in COVID-19 survivors, linked to the severity of impaired gas transfer and, therefore, lung damage. However, this relationship wasn't strong, so screening for lung function impairment should continue to use traditional spirometry and gas

transfer in patients who have symptoms compatible with post-COVID-19 lung changes.

The reasons for abnormal breathing patterns could be the result of (a) obesity, (b) COVID-19 itself causing pneumonia, leading to sepsis, and producing delirium, (c) the effects of sedation and medication on breathing centres, or (d) mechanical ventilation and oxygen therapy.

It is well established that the work of breathing is increased and the total respiratory compliance is decreased in obesity [19]. This could be a cause of altered breathing patterns, although there is no obvious link between the two in this data. Further work is being undertaken to explore these breathing patterns in more detail.

### Limitations

The potential errors with lung function testing have been minimised since all testing was performed on calibrated equipment and was measured by experienced, well-trained personnel. In addition, all equipment was monitored with a stringent quality control protocol, including both physical and biological quality control, within tests quality checks and review of all tests by senior physiologists [7, 8]. Furthermore the  $V_A/TLC$  ratio in the subgroup who had lung volumes measured showed  $V_A$  to be on average within 7% of TLC, which indicates good consistency and test quality. Unfortunately, we were unable to perform lung volume measurements in all patients due to limited lung function timeslots.

Our population and their treatment may be different from other centres who have published lung function data in COVID-19. Certainly the body habitus of the data from Mo et al. [2] shows normal BMI values, unlike our population who were predominantly obese/overweight. However, the ventilation regimens adopted in the UK and at our centre were based around the WHO guidance for COVID-19 following experience from Wuhan early in the pandemic [1].

We didn't measure muscle pressures as this wasn't a prospective study. However, Huang et al. [3] found no abnormalities in respiratory muscle function. We also didn't measure abdominal obesity as this may have a different effect on gas transfer compared with upper body obesity.

Changes we have seen may not just be due to COVID-19 directly but, also, therapeutic insults/interactions (e.g. corticosteroids, oxygen, and mechanical ventilation) or other pathophysiological events such as delirium or sepsis. However, similar regimens were used across world after the Wuhan experience was published. Nevertheless, the physiological changes in this population will remain a legacy for many patients who have had COVID-19 and will add further demands to already over-subscribed,

limited in performance lung function facilities worldwide [40]. Consequently, because of aerosol-generating properties of lung function testing and the difficulties delivering testing [40], it has not been possible to test all patients at the same time since hospital discharge.

The reference values for breathing patterns (using SLP) are a recently derived and validated set of reference values and may not be good at discriminating normal from abnormal.

In summary, we have been able to identify common pattern of restrictive pulmonary impairment in COVID-19 recovery but not the specific causes. There are many potential contributing factors both directly related to the infection but, also, other patient-specific factors such as co-morbidities, treatment regimes, length of stay, physical fitness, etc. In addition, radiological data and symptom scores were not available. Due to the multifaceted nature of the clinical outcome in COVID-19, it would most likely require a much larger population with additional information to elicit the specific pathologies that induce these physiological effects.

### Future work

Future work should measure  $TL_{NO}$  or  $Dm/Vc'$  in COVID-19 so that the vascular component and membrane components of the gas transfer processes can be better understood. It would be expected that a pattern consistent with altered capillary blood volume may become evident.

Some patients in our post-COVID-19 clinics will have further follow-up lung function after another 3+ months, so it will be interesting to see if the changes we have found (particularly in gas transfer) are related to any change in body habitus or to the repair of the suspected lung damage we have highlighted here. Further analysis of the breathing pattern data may show subtle differences in breathing patterns between the two groups.

### Summary

We found similar restrictive patterns (reduced vital capacity and alveolar volume) in survivors with moderate and severe COVID pneumonitis whether admitted to wards or ITU. There is often a mild reduction in gas transfer ( $TL_{CO}$ ) but a preservation/ relative rise in transfer coefficient ( $K_{CO}$ ). These results can be explained partly by obesity (causing extrapulmonary restriction) but perhaps also by haemosiderosis from lung damage and localised microvascular changes in lung capillaries. Potential respiratory muscle fatigue/weakness is unlikely to be a causal factor in our study.

Abnormal breathing patterns (outside 1.64 SRs) of reference data showed 20% of subjects displayed one or more abnormality of breathing in duty cycle, phase angle

and respiratory rate. However, no consistent breathing pattern abnormalities were evident. The use of common breathing pattern indices to screen post-COVID-19 patients for those who require more extensive lung function testing isn't borne out in our population.

## Conclusion

We conclude that the residual changes in lung function and breathing patterns observed at 3+ months are similar whether patients attended wards or were mechanically ventilated on ITU, despite a minor (albeit statistically significant) difference in  $K_{CO}$ . Understanding the patterns of physiological abnormality post-COVID-19 could help direct clinical management of these patients during their recovery.

## Abbreviations

BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; COVID-19: Coronavirus Disease 2019; CPAP: Continuous Positive Airway Pressure; Dm: Membrane Diffusing Capacity; ECSC: European Coal and Steel Community; FEV1: Forced Expired Volume in 1 Second;  $FiO_2$ : Fraction of Inspired Oxygen; FVC: Forced Vital Capacity; GLI: Global Lung Initiative; ICUAW: Intensive Care Unit Acquired Weakness; IE50: Inspiratory:Expiratory Flow Ratio at 50% Tidal Volume; IQR: Interquartile Range; ITU: Intensive Therapy Unit;  $K_{CO}$ : Transfer Coefficient for Carbon Monoxide; MERS: Middle East Respiratory Syndrome; NIV: Non-Invasive Ventilation; PA: Phase Angle; PEF: Peak Expiratory Flow; RMSSD: Root Mean Square of the Successive Differences between Each Breath; RR: Respiratory Rate; RTC: Relative Thoracic Contribution; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; SDBB: Standard Deviation of Breath to Breath; SE: Standard Error of the Mean; SLP: Structured Light Plethysmography; SR: Standardised Residuals;  $Ti/Ttot$ : Inspiratory Time/Total Breath Time (Duty Cycle); TLC: Total Lung Capacity;  $TL_{CO}$ : Transfer Factor for Carbon Monoxide;  $TL_{NO}$ : Transfer Factor for Nitric Oxide;  $V_A$ : Alveolar Volume; VC: Vital Capacity (Relaxed);  $V_c$ : Pulmonary Capillary Volume;  $V_i$ : Inspired Volume.

## Acknowledgements

Not applicable.

## Authors' contributions

JAS managed the lung function testing, collated and analysed the data (with the exception of the entropy data), and produced the manuscript. EAA performed the structured light plethysmography and analysed the entropy data under the supervision and guidance of AMC. DP, NG and SCM were responsible for the care of patients on ITU and respiratory wards. DP, TG, NG and SCM formed the post-discharge medical team for the management of all patients. BGC oversaw all aspects of the study and contributed significantly to the production of the manuscript. All authors approved the submitted version of the manuscript.

## Funding

Dr Dhruv Parekh is supported but United Kingdom Research and Innovation (UKRI) and the National Institute for Health Research (NIHR).

## Availability of data and materials

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

## Declarations

### Ethics approval and consent to participate

This work uses data provided by patients and collected by the NHS as part of their care and support at University Hospitals Birmingham NHS Foundation Trust. As such, neither written informed consent nor ethical approval was

required. This has been approved by University Hospitals Birmingham NHS Foundation Trust Clinical Audit Registration & Management System (Audit Code: CARMS-16371).

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Lung Function and Sleep, Outpatient Department Area 3, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2GW, UK. <sup>2</sup>School of Biomedical Sciences, Institute of Clinical Sciences, University of Birmingham, Birmingham, UK. <sup>3</sup>College of Sciences and Health Professions, Basic Sciences Department, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. <sup>4</sup>Critical Care, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK. <sup>5</sup>Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, UoB, Birmingham, UK. <sup>6</sup>Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK. <sup>7</sup>Respiratory Medicine, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK.

Received: 2 March 2021 Accepted: 29 August 2021

Published online: 27 September 2021

## References

- WHO-coronavirus disease (COVID-19) Situation report—137, June 5, 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>.
- Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. *Eur Respir J*. 2020. <https://doi.org/10.1183/13993003.01217-2020>.
- Huang Y, Tan C, Wu J, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. *Respir Res*. 2020;21:163.
- You J, Zhang L, Ti MN, et al. Abnormal pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients after discharge. *Lett. J Infection*. 2020;81(2):E150–2.
- Fumagalli A, Misuraca C, Bianchi A, et al. Pulmonary function in patients surviving to COVID-19 pneumonia. *Infection*. 2021;49:153–7.
- George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. *Thorax*. 2020;75:1009–16.
- Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. *Eur Respir J*. 2005;26:153–61.
- Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26:319–38.
- Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. *Eur Respir J*. 2005;26:511–22.
- MacIntyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J*. 2005;26:720–35.
- Guidelines for the measurement of respiratory function. Recommendations of the British thoracic Society and the association of respiratory technicians and Physiologists. *Respir Med*. 1994;88:165–94.
- Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012;40:1324–43.
- Quanjer PH, ed. Standardized lung function testing. Report Working Party Standardization of Lung Function Tests. European Community for Coal and Steel. *Bull Eur Physiopathol Respir*. 1983; 19(Suppl 5): 1–95.
- Motamedi-Fakhr S, Wilson RC, Iles R. Tidal breathing patterns derived from structured light plethysmography in COPD patients compared with healthy subjects. *Med Devices (Auckl)*. 2016;10:1–9.
- Lauhkonen E, Cooper BG, Iles R. Mini review shows that structured light plethysmography provides a non-contact method for evaluating breathing patterns in children. *Acta Paediatrica*. 2019;108(8):1398–405.
- Fakhr MS, Barker N, Alexander J, et al. A preliminary set of growth adjusted reference equations for Structured light plethysmography (SLP). *Eur Respir J*. 2020;56(Suppl 64):855.

17. Geberhiwot T, Madathil S, Gautam N. After care of survivors of COVID-19—challenges and a call to action. *JAMA Health Forum*. 2020. <https://doi.org/10.1001/jamahealthforum.2020.0994>.
18. Hughes JMB, Pride NB. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. *Am J Respir Crit Care Med*. 2012;186:132–9.
19. Salome CM, King G, Nberend GG. Physiology of obesity and effects on lung function. *J App Physiol*. 2010;108(1):206–11.
20. O'Donnell DE, Ciavaglia CE, Neder JA. When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences. *Ann Am Thoracic Soc*. 2014;11(4):635–44.
21. Collins LC, Hobery PD, Walker JF, et al. The effect of body fat distribution on pulmonary function tests. *Chest*. 1995;107(5):1298–302.
22. Neder JA, Berton DC, Odonnell DE. Obesity: how pulmonary function tests may let us down. *J Bras Pneumol*. 2020. <https://doi.org/10.36416/1806-3756/e20200116> (Epub June 15).
23. Lipscomb DJ, Patel K, Hughes JMB. Interpretation of increases in the transfer coefficient for carbon monoxide (TLco/VA or Kco). *Thorax*. 1978;33:728–33.
24. Zavorsky GS, Kim DJ, McGregor ER. Pulmonary diffusing capacity for nitric oxide during exercise in morbid obesity. *Obesity*. 2008;16:2431–8.
25. Zhou S, Wang Y, Zhu T, et al. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 Patients in Wuhan, China. *Am J Roentgenol*. 2020;214:1287–94.
26. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis*. 2020;20:425.
27. Xiong Y, Sun D, Liu Y, et al. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes. *Invest Radiol*. 2020. <https://doi.org/10.1097/RLI.0000000000000674>.
28. Liu D, Zhang W, Pan F, et al. The pulmonary sequelae in discharged patients with COVID-19: a short-term observational study. *Respir Res*. 2020;21:125.
29. Li K, Wu J, Wu F, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. *Invest Radiol*. 2020. <https://doi.org/10.1097/RLI.0000000000000672>.
30. Liu XX, Guoqiang Q, Wang Y. A observational autopsy report of COVID-19 and at follow-up. *J Forensic Med*. 2020;36:19–21.
31. Mentzer SJ, Konerding MA. Intussusceptive angiogenesis: expansion and remodelling of microvascular networks. *Angiogenesis*. 2014;17(3):499–509.
32. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med*. 2020;383(2):120–8.
33. Sherman JM, Winnie G, Thomassen MJ, et al. Time course of hemosiderin production and clearance by human pulmonary macrophages. *Chest*. 1984;86:409–11.
34. Epstein CE, Elidemir O, Colasurdo GN, et al. Time course of hemosiderin production by alveolar macrophages in a murine model. *Chest*. 2001;120:2013–20.
35. Hughes JMB. The single breath transfer factor (TI, co) and the transfer coefficient (Kco): a window onto the pulmonary microcirculation. *Clin Physiol Funct Imag*. 2003;23:63–71.
36. Vas P, Hopkins D, Feher M, et al. Diabetes, obesity and COVID-19: a complex interplay. *Diabetes Obes Metab*. 2020;22:1892–6.
37. Hui DS, Joynt GM, Wong KT, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. *Thorax*. 2005;60(5):401–9.
38. Sapey E, Gallier S, Mainey C, et al. Ethnicity and risk of death in patients hospitalised for COVID-19 infection in the UK: an observational cohort study in an urban catchment area. *BMJ Open Respir Res*. 2020;7(1):000644.
39. Farsalinos K, Barbouni A, Poulas K, et al. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. *Ther Adv Chronic Dis*. 2020;11:2040622320935765.
40. Hull J, Lloyd JK, Cooper BG. Spotlight: lung function testing in the COVID-19 endemic. *Lancet Respir Med*. 2020;8(7):P666. [https://doi.org/10.1016/S2213-2600\(20\)30246](https://doi.org/10.1016/S2213-2600(20)30246).

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

